Cho Esther 4

What Happened

• Esther Cho, SVP and General Counsel of Keros Therapeutics (KROS), was granted a derivative award of 80,000 shares reported as acquired on Feb 24, 2026. The reported price is $0.00, and the filing was made on Feb 26, 2026. This is a compensation award (an option grant per the footnote), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (filed within two business days).
• Reported consideration/price: $0.00 (derivative award).
• Shares acquired: 80,000 (derivative — option).
• Shares owned after transaction: not specified in the information provided.
• Footnote (vesting): 1/4 vests on Feb 24, 2027; the remaining shares vest in 12 substantially equal quarterly installments thereafter, subject to continued service.
• No indication this was a cashless exercise or immediate sale.

Context

• This filing documents an option/award grant used for compensation or retention. Vesting begins one year after the grant with quarterly vesting thereafter, so the award is subject to continued employment and is not immediately tradable income. Grants are routine for executives and do not by themselves indicate buying or selling intent.